Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM for organ failure in COVID-19 Patients ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Enlivex Therapeutics"},{"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Enlivex Therapeutics"},{"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces a New Publication \u201cApoptotic Cell Therapy for Cytokine Storm Associated with Acute Severe Sepsis\u201d in Cell Death & Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Enlivex Therapeutics"},{"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Enlivex Therapeutics"},{"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Enlivex Therapeutics"},{"company":"NanoPass Technologies","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoPass's Intradermal Delivery Platform Used in Emergex's Next-Generation COVID-19 Vaccination Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"NanoPass Technologies"}]

NanoPass Technologies

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

NanoPass's Intradermal Delivery Platform Used in Emergex's Next-Generation COVID-19 Vaccination Study

Details:

NanoPass is partnering with Emergex for multiple COVID vaccine LD PepGNP-SARSCoV2, to demonstrate that its drug delivery platform, the MicronJet® 600 can reduce the dose of any vaccine as well as improve immune responses using equivalent doses.

Lead Product(s): LD PepGNP-SARSCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: LD PepGNP-SARSCoV2

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Emergex Vaccines Holding

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 26, 2022

ASK
US

Upload
your Pipeline Activity

Enlivex Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy

Details:

ALLOCETRATM has been designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19.

Lead Product(s): Allocetra-OTS

Therapeutic Area: Infections and Infectious Diseases Product Name: Allocetra

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 16, 2020

ASK
US

Upload
your Pipeline Activity

Enlivex Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy

Details:

ALLOCETRATM targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating such tumors' microenvironment.

Lead Product(s): Allocetra-OTS

Therapeutic Area: Infections and Infectious Diseases Product Name: Allocetra

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2020

ASK
US

Upload
your Pipeline Activity

Enlivex Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enlivex Announces a New Publication “Apoptotic Cell Therapy for Cytokine Storm Associated with Acute Severe Sepsis” in Cell Death & Disease

Details:

Preclinical data from the studies demonstrate the ability of AllocetraTM to broadly resolve cytokine storm-associated organ failure and reduce mortality by 90% in a murine cecal ligation and puncture (CLP) animal model of severe sepsis.

Lead Product(s): Allocetra-OTS

Therapeutic Area: Infections and Infectious Diseases Product Name: Allocetra

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

ASK
US

Upload
your Pipeline Activity

Enlivex Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra

Details:

The primary aim of the clinical trial was to determine the safety profile and tolerability of Off-The-Shelf Allocetra in Patients with Severe Sepsis.

Lead Product(s): Allocetra-OTS

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

ASK
US

Upload
your Pipeline Activity

Enlivex Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM for organ failure in COVID-19 Patients

Details:

Enlivex has publicly announced its plan to initiate in 2020 two clinical studies: (i) a Phase II/III clinical trial for sepsis later in the year, and (ii) a Phase II/III for the prevention of GvHD.

Lead Product(s): Allocetra

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY